Asit Parikh (L) and Reid Huber

Ex­clu­sive: Third Rock­'s stealthy MO­MA Ther­a­peu­tics taps a long­time Mil­len­ni­um, Take­da vet as CEO

In the weeks af­ter the Boston area first shut down for the pan­dem­ic, Asit Parikh picked up a phone and, di­al­ing Take­da R&D chief Andy Plump, de­cid­ed to end the 14-year-chap­ter that com­prised al­most the en­tire­ty of his pro­fes­sion­al ca­reer. Parikh joined Take­da in the 2008 Mil­len­ni­um Phar­ma­ceu­ti­cals buy­out; he led clin­i­cal stud­ies on what would be­come the block­buster En­tyvio and since 2014 ran the Big Phar­ma’s GI di­vi­sion. But the pan­dem­ic had a way of mak­ing every­one take stock. “I al­ways want­ed big chal­lenges,” he said. “It was time.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.